(Q37124978)

18 August 2017

1 reference

title

A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/ Humate -P: history and clinical performance (English)

1 reference

18 August 2017

5

Massimo Franchini

1 reference

18 August 2017

Pier Mannuccio Mannucci

9

object named as

Pier M Mannucci

1 reference

18 August 2017

4

Augusto B Federici

1 reference

18 August 2017

Erik Berntorp

1

1 reference

18 August 2017

William Archey

2

1 reference

18 August 2017

Günter Auerswald

3

1 reference

18 August 2017

Sigurd Knaub

6

1 reference

18 August 2017

Wolfhart Kreuz

7

1 reference

18 August 2017

Stefan Lethagen

8

1 reference

18 August 2017

Hartmut Pollmann

10

1 reference

18 August 2017

Inge Scharrer

11

1 reference

18 August 2017

Keith Hoots

12

1 reference

18 August 2017

publication date

1 May 2008

1 reference

European journal of haematology. Supplementum

18 August 2017

published in

1 reference

18 August 2017

issue

70

1 reference

18 August 2017

page(s)

3-35

1 reference

Characterization of a core binding site for ADAMTS-13 in the A2 domain of von Willebrand factor.

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

von Willebrand factor and platelet function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Insight into the structure, function, and biosynthesis of factor VIII through recombinant DNA technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Von Willebrand disease within the collective of haemophilic patients as reason for unexpected bleeding episodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Acquired von Willebrand syndrome: an underdiagnosed and misdiagnosed bleeding complication in patients with lymphoproliferative and myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Acquired von Willebrand syndrome: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Immune-mediated etiology of acquired von Willebrand syndrome in systemic lupus erythematosus and in benign monoclonal gammopathy: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Acquired von Willebrand syndrome in aortic stenosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Appendix II: A revised classification of Von Willebrand disease*: For The Subcommittee on Von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Laboratory diagnosis of congenital von Willebrand disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Proteolysis of von Willebrand factor and shear stress-induced platelet aggregation in patients with aortic valve stenosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

A rare hemostatic disorder: pseudo von Willebrand's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Diagnosis of inherited von Willebrand disease: a clinical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

A simple and accurate microplate assay for the determination of factor VIII activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Retrospective review of the management of elective surgery with desmopressin and clotting factor concentrates in patients with von Willebrand disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Use of ristocetin cofactor activity in the management of von Willebrand disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Diagnosis and management of von Willebrand disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Prophylaxis and treatment of bleeding complications in von Willebrand disease type 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Clinical experience of prophylactic treatment in von Willebrand disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Consensus perspectives on prophylactic therapy for haemophilia: summary statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Dental extractions in patients with bleeding disorders. The use of fibrin glue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

The role of self-infusion treatment for the patient with haemophilia (author's transl)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 years follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Induction of immune tolerance in haemophilia A inhibitor patients by the 'Bonn Protocol': predictive parameter for therapy duration and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Tolerance induction using the Malmö treatment model 1982-1995.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

The epidemiology of inhibitors in haemophilia A: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Haemophilic patients with inhibitors to factor VIII or IX: variables affecting treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Analysis of the North American Immune Tolerance Registry (NAITR) 1993-1997: current practice implications. ISTH Factor VIII/IX Subcommittee Members

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Treatment of von Willebrand's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Management of inherited von Willebrand disease in 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Comparison of the in vitro characteristics of von Willebrand factor in British and commercial factor VIII concentrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Characterization of factor VIII/von Willebrand factor concentrates using a modified method of von Willebrand factor multimer analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Von Willebrand factor containing factor VIII concentrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Prevalence of antibodies to hepatitis C virus (HCV) in haemophiliacs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Safety of pasteurised factor VIII (haemate HS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Pharmacokinetics, efficacy and safety of Humate-P in von Willebrand disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate-P).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Pharmacokinetics of two pasteurized Factor VIII concentrates by different and multicenter assays of Factor VIII activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Absence of hepatitis after treatment with a pasteurized factor VIII concentrate in patients with hemophilia and no previous transfusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Clinical use of Haemate P in inherited von Willebrand's disease: a cohort study on 100 Italian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Dental procedures in adult patients with hereditary bleeding disorders: 10 years experience in three Italian Hemophilia Centers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

A comparative in vitro evaluation of six von Willebrand factor concentrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Cleavage of ultralarge multimers of von Willebrand factor by C-terminal-truncated mutants of ADAMTS-13 under flow

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Absence of anti-human immunodeficiency virus types 1 and 2 seroconversion after the treatment of hemophilia A or von Willebrand's disease with pasteurized factor VIII concentrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Absence of hepatitis A after treatment with pasteurised factor VIII concentrates in children with haemophilia A and von Willebrand disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Deep venous thrombosis in hemophilia A

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Thrombosis in a duplicated superficial femoral vein in a patient with haemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Virus safety of pasteurized clotting factor concentrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Transmission of hepatitis C with pasteurised factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

von Willebrand disease: laboratory aspects of diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

Low recovery in vivo of highly purified factor VIII in patients with hemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01049.X

10.1111/J.1600-0609.2008.01049.X

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference